Pharmaceuticals

Company Overview of Dr. Falk Pharma GmbH

Company Overview

Dr. Falk Pharma GmbH develops and sells prescription medications for hepatology and gastroenterology. The company sells its products through local partners and its subsidiary companies in Germany and internationally. Dr. Falk Pharma GmbH was formerly known as Dr. Falk Arzneimittel GmbH & Co KG and changed its name to Dr. Falk Pharma GmbH in 1989. The company was founded in 1960 and is based in Freiburg, Germany.

Key Executives for Dr. Falk Pharma GmbH

Managing Director, Member of Executive Board, President of The Falk Foundation E.V. and Director of Falk Foundation e. V.

Compensation as of Fiscal Year 2014.

Dr. Falk Pharma GmbH Key Developments

Medigene AG Enters into Licensing Agreement with Dr Falk Pharma GmbH

Mar 19 14

Medigene AG has entered into an exclusive global licensing agreement with Dr. Falk Pharma GmbH for the development and commercialization of its drug candidate RhuDex for indications in hepatology and gastroenterology. Falk Pharma will assume responsibility and all costs relating to the clinical development and marketing of RhuDex in these therapeutic areas. Medigene will receive an upfront payment and future milestone payments from Falk Pharma, plus double-digit RhuDex royalties.

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.